Highlights
- Total Revenue (TTM)
- $562.12M
- Gross Profit (TTM)
- $538.73M
- EBITDA (TTM)
- -$131.05M
- Year Range
- $73.04 - $129.65
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Blueprint Medicines Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Blueprint Medicines Corporation
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 29.02% | -14.18% | -8.35% | 1.12% | 13.24% | 26.47% | 1.00% | 48.43% | |||||
| 2024 | -13.78% | 17.59% | 1.43% | -3.71% | 15.57% | 2.10% | 0.48% | -11.78% | -3.18% | -5.39% | 10.14% | -9.50% | -5.44% |
| 2023 | 6.69% | -9.35% | 6.18% | 13.47% | 10.71% | 11.82% | 4.43% | -24.45% | 0.72% | 17.20% | 18.31% | 32.45% | 110.55% |
| 2022 | -28.02% | -21.47% | 5.50% | -8.66% | -5.74% | -8.16% | 1.09% | 43.40% | -10.01% | -21.32% | -7.81% | -8.33% | -59.10% |
| 2021 | -13.73% | 1.52% | -1.01% | -0.94% | -5.16% | -3.71% | -0.10% | 6.15% | 10.23% | 9.42% | -14.48% | 11.34% | -4.49% |
| 2020 | -20.80% | -14.69% | 8.04% | 0.60% | 10.73% | 19.74% | -6.18% | 5.81% | 19.72% | 10.33% | 5.67% | 3.77% | 40.00% |
Benchmark Metrics
Blueprint Medicines Corporation has an annualized alpha of 21.71%, beta of 1.19, and R² of 0.15 versus S&P 500 Index. Calculated based on daily prices since May 01, 2015.
- This stock captured 160.13% of S&P 500 Index gains and 118.74% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.15 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 21.71%
- Beta
- 1.19
- R²
- 0.15
- Upside Capture
- 160.13%
- Downside Capture
- 118.74%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Blueprint Medicines Corporation (BPMC) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Blueprint Medicines Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Blueprint Medicines Corporation was 69.50%, occurring on Feb 24, 2023. Recovery took 568 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -69.5% | Dec 24, 2020 | 545 | Feb 24, 2023 | 568 | Jun 2, 2025 | 1113 |
| -62.86% | Jun 19, 2015 | 161 | Feb 8, 2016 | 198 | Nov 17, 2016 | 359 |
| -55.74% | Mar 16, 2018 | 195 | Dec 21, 2018 | 459 | Oct 19, 2020 | 654 |
| -32.79% | Nov 25, 2016 | 13 | Dec 13, 2016 | 59 | Mar 10, 2017 | 72 |
| -27.1% | May 2, 2017 | 20 | May 30, 2017 | 18 | Jun 23, 2017 | 38 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Blueprint Medicines Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Blueprint Medicines Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |